<< FRC applauds FDA for rejecting over-the-counter pill in America's pharmacies | Launch of myDNA.com breast cancer channel >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Filipino | עִבְרִית | Bahasa | Norsk | Русский | Svenska | Polski

Study shows Chromium Picolinate and Biotin Combination significantly lowers coronary risk factors in people with Type 2 Diabetes

Published on May 6, 2004 at 8:08 PM · No Comments
Results of a new double-blind, placebo-controlled, randomized clinical study show that daily nutritional supplementation with a combination of chromium picolinate and biotin (marketed as Diachromeä) significantly improved coronary risk factors in people with type 2 diabetes. The clinical study, which evaluated 24 patients over 30 days, was presented today at the AHA’s Annual Conference on Arteriosclerosis, Thrombosis & Vascular Biology (ATVB) in San Francisco.  

The study found the following significant improvements in subjects who added Diachrome, to their treatment regimen:

  • Total cholesterol levels dropped an average of 19.1 mg/dL
  • LDL (“bad”) cholesterol levels dropped an average of 10.9 mg/dL
  • Average fasting blood glucose (FBG) levels decreased 26.2 mg/dL
  • Apo-B dropped -5.3 mg/dl
  • Ratio of apo-B/apo-A; LDL-C/HDL-C improved

“This study emphasizes that Diachrome not only improves blood sugar levels, but decreases LDL cholesterol which will help people with diabetes meet the ATP III guidelines for cholesterol which is difficult for them to achieve, “ states Jeffrey Geohas, MD, principal investigator, medical director, Radiant Research, Chicago. “Diachrome should be considered as an important adjunct therapy to statins and diet in lowering LDL cholesterol.”

All study subjects had type 2 diabetes for at least one year. They exhibited poorly controlled blood glucose levels, as measured by fasting blood glucose (FBG) above 200 mg/dL and elevated glycosylated hemoglobin (HbA1c) above 7%, despite taking anti-diabetic medications for at least six months. Subjects were divided into two groups to randomly receive either Diachrome or placebo daily, while continuing their prescription medications. The 30-day measurements also showed a decrease in average triglyceride levels, although it was not statistically significant. 

“While Diachrome continues to show effectiveness in improving blood glucose levels for people with type 2 diabetes, evidence is also building as to positive effects on coronary risk factors,” explains Anne Daly, MS, RD, BC-ADM, CDE, author and expert in diabetes care and education. “These data indicate the need for further study into the potential for Diachrome to help prevent cardiovascular disease, which is the leading cause of diabetes-related death.”

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading